IKCS 2021

Complete Coverage

COVID-19 Vaccines Deemed Safe for Renal Cell Carcinoma Patients on Immune Checkpoint Inhibitors

By

Sucharita Mistry, PhD

The rate of new or worsening immune-related adverse events was no higher than previously reported.

Cytoreductive Nephrectomy Plus Active Surveillance Benefits Some With Metastatic Renal Cell Carcinoma

By

Jonathan Goodman, MPhil

The median cancer-specific survival was 56.5 months.

Managing Adverse Reactions to Lenvatinib-Pembrolizumab

By

Sucharita Mistry, PhD

The median time to first onset of key adverse reactions was within 5 months of starting lenvatinib-pembrolizumab.

Gene Expression Profiling Could Inform Treatment of Non-Clear Cell Renal Cell Carcinoma

By

Jonathan Goodman, MPhil

Nearly half of non-clear cell renal cell carcinoma samples were classified as proliferative.

Predicting Long-Term Survival With Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma

By

Jonathan Goodman, MPhil

Patients with smaller target lesions at baseline were more likely to be long-term survivors.

High IC and HU Associated With Better Outcomes in Metastatic Renal Cell Carcinoma

By

Jonathan Goodman, MPhil

Iodine concentration and Hounsfield units were associated with treatment response and survival.

COVID-19 Vaccination Yields High Seroconversion Rates in Renal Cell Carcinoma

By

Jonathan Goodman, MPhil

The seroconversion rate was 92%.

Lenvatinib Plus Pembrolizumab Improves Long-Term Outcomes in Advanced Renal Cell Carcinoma

By

Jonathan Goodman, MPhil

It was previously unknown whether the survival benefits seen with lenvatinib plus pembrolizumab persisted in the long term.

Real-World Characteristics and Treatment Patterns in Advanced Renal Cell Carcinoma Treated With First-Line Avelumab Plus Axitinib

By

Lauren Dembeck, PhD

Researchers determined that few patients with poor risk aRCC were receiving first-line avelumab plus axitinib.

First-Line Nivolumab Plus Ipilimumab May Offer Greater Cost Efficiency Than Pembrolizumab Plus Axitinib in Advanced Renal Cell Carcinoma

By

Lauren Dembeck, PhD

The monthly incremental cost per survivor relative to sunitinib for nivolumab plus ipilimumab decreased over time from $90,035 for 12 months to $18,881 for 48 months.

Oncologists Appear to Prefer IO/IO to IO/TKI Combinations in First-Line Metastatic Renal Cell Carcinoma

By

Lauren Dembeck, PhD

The investigators aimed to understand how oncologists decide between IO/IO and IO/TKI treatment options via survey.

BRCA1-Associated Protein 1 Suppresses Tumor Growth via Interferon-β in Clear Cell Renal Cell Carcinoma

By

Lauren Dembeck, PhD

Patients with BAP1-mutant ccRCC have very poor prognosis and comprise 10% to 15% of ccRCC cases.

Adverse Radiologic and Pathologic Features Predict Worse Survival Outcomes in Small Renal Masses Following Nephrectomy

By

Lauren Dembeck, PhD

Researchers hypothesized that adverse radiologic and pathologic T3 features are predictive of worse outcomes in small renal masses.

5-year Follow Up: First-Line Nivolumab Plus Ipilimumab vs Sunitinib in Advanced Renal Cell Carcinoma

By

Lauren Dembeck, PhD

Investigators presented the longest phase 3 follow up reported for a checkpoint inhibitor combination therapy in aRCC.

Disease-Free Survival Predicts Overall Survival in Localized Renal Cell Carcinoma After First Nephrectomy

By

Lauren Dembeck, PhD

Investigators assessed the association between DFS and OS in patients with newly diagnosed, completely resected, intermediate-high or high-risk RCC post-nephrectomy.

Nivolumab Plus Cabozantinib Improves Outcomes Relative to Sunitinib in Patients With Advanced Renal Cell Carcinoma and Bone Metastasis

By

Lauren Dembeck, PhD

A total of 651 patients with clear cell aRCC were randomly assigned to receive nivolumab plus cabozantinib or sunitinib.

Active Management Improves Adverse Event Outcomes Among Patients With Advanced Renal Cell Carcinoma Receiving Axitinib Plus a Checkpoint Inhibitor

By

Lauren Dembeck, PhD

A retrospective physician-administered chart review evaluated AEs and management strategies used in United States clinical practice among adult patients with aRCC.

Radiation Prior to Immunotherapy May Not Affect Outcomes in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases

By

Lauren Dembeck, PhD

No major difference in outcome was observed in a retrospective analysis of patients with mRCC and bone metastasis treated with IO with and without prior radiation.